Innate Pharma - Gilde Healthcare

Innate Pharma


Marseille, France

Cancer Immunotherapeutics
Since: 2002
Exit: 2005

Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.

Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.

Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.

More Innate Pharma news

Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million

INNATE PHARMA initiates collaboration with Celgene

Innate Pharma reports positive phase IIa in type C viral hepatitis

INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights